Literature DB >> 12639641

Retroperitoneoscopic nephroureterectomy for transitional cell carcinoma of the renal pelvis and ureter: Nagoya experience.

Yasushi Yoshino1, Yoshinari Ono, Ryohei Hattori, Momokazu Gotoh, Osamu Kamihira, Shinichi Ohshima.   

Abstract

OBJECTIVES: To evaluate the efficacy of our new retroperitoneoscopic nephroureterectomy for patients with transitional cell carcinoma of the renal pelvis and ureter, we present the operative procedure and analysis of the clinical outcome of retroperitoneoscopy in 23 patients.
METHODS: Twenty-three patients with transitional cell carcinoma of the upper urinary tract underwent retroperitoneal laparoscopic nephroureterectomy between February 2000 and February 2002. Patient age ranged from 44 to 83 years (mean 66.7). Each kidney was retroperitoneoscopically dissected en bloc, together with the perirenal fatty tissue, lymph nodes, and/or adrenal gland, without transecting the ureter. The lower ureter was resected with the bladder cuff transected using an ultrasonic scalpel and an endoscopic gastrointestinal automatic stapler. The dissected specimen was removed intact through a 6-cm-long original incision.
RESULTS: The mean operating time was 4.8 hours, including 0.7 hours for complete removal of the ureteral end with the bladder cuff. The mean estimated blood loss was 304 mL. The mean time to recovery to normal activity was 18 days. In the mean follow-up period of 15 months, 2 patients died of cancer progression in the sixth postoperative month, 2 died of other causes, and 4 had recurrent transitional cell carcinoma of the bladder after surgery.
CONCLUSIONS: Our retroperitoneal laparoscopic nephroureterectomy using an endoscopic gastrointestinal automatic stapler is a fast, low-risk, and minimally invasive procedure and might be an alternative to other laparoscopic techniques and open nephroureterectomy. However, long-term follow-up is necessary to confirm the efficacy for patients with transitional cell carcinoma of the renal pelvis and ureter.

Entities:  

Mesh:

Year:  2003        PMID: 12639641     DOI: 10.1016/s0090-4295(02)02410-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  [Comparison of efficacy and safety between two different methods of nephroureterectomy in two centers].

Authors:  J F Wu; R C Lin; Y C Lin; W H Cai; Q G Zhu; D Fang; G Y Xiong; L Zhang; L Q Zhou; L F Ye; X S Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

2.  Treatment of upper tract urothelial carcinoma: a review of surgical and adjuvant therapy.

Authors:  Kalyan C Latchamsetty; Christopher R Porter
Journal:  Rev Urol       Date:  2006

3.  Systematic review of open versus laparoscopic versus robot-assisted nephroureterectomy.

Authors:  Emma Mullen; Kamran Ahmed; Ben Challacombe
Journal:  Rev Urol       Date:  2017

4.  Pure laparoscopic complete excision of distal ureter with a bladder cuff for upper tract urothelial carcinoma.

Authors:  Ryohei Hattori; Yasushi Yoshino; Tomonori Komatsu; Yoshihisa Matsukawa; Yoshinari Ono; Momokazu Gotoh
Journal:  World J Urol       Date:  2008-10-10       Impact factor: 4.226

5.  Retroperitoneal nephroureterectomy with excision of cuff of the bladder for upper urinary tract transitional cell carcinoma: comparison of laparoscopic and open surgery with long-term follow-up.

Authors:  Ashok K Hemal; Anup Kumar; Narmada P Gupta; Amlesh Seth
Journal:  World J Urol       Date:  2008-04-23       Impact factor: 4.226

6.  Comprehensive management of upper tract urothelial carcinoma.

Authors:  Georgios Koukourakis; Georgios Zacharias; Michael Koukourakis; Kiriaki Pistevou-Gobaki; Christos Papaloukas; Athanasios Kostakopoulos; Vassilios Kouloulias
Journal:  Adv Urol       Date:  2008-12-10

7.  Comparison between completely and traditionally retroperitoneoscopic nephroureterectomy for upper tract urothelial cancer.

Authors:  Lin Yao; Kunlin Yang; Xuesong Li; Zheng Zhang; Cuijian Zhang; Kan Gong; Zhijun Xi; Zhisong He; Liqun Zhou
Journal:  World J Surg Oncol       Date:  2016-06-28       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.